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Abstract This study was undertaken to determine if the
ketogenic diet could be useful for glioblastoma patients.
The hypothesis tested was whether glioblastoma cells can
metabolize ketone bodies. Cerebellar astrocytes and C6
glioblastoma cells were incubated in glutamine and serum
free medium containing [2,4-
13C]b-hydroxybutyrate
(BHB) with and without glucose. Furthermore, C6 cells
were incubated with [1-
13C]glucose in the presence and
absence of BHB. Cell extracts were analyzed by mass
spectrometry and media by
1H magnetic resonance spec-
troscopy and HPLC. Using [2,4-
13C]BHB and [1-
13C]glu-
cose it could be shown that C6 cells, in analogy to
astrocytes, had efﬁcient mitochondrial activity, evidenced
by
13C labeling of glutamate, glutamine and aspartate.
However, in the presence of glucose, astrocytes were able
to produce and release glutamine, whereas this was not
accomplished by the C6 cells, suggesting lack of anaple-
rosis in the latter. We hypothesize that glioblastoma cells
kill neurons by not supplying the necessary glutamine, and
by releasing glutamate.
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Introduction
Glioblastoma is the most malignant brain tumour forming
50% of all primary brain carcinomas. Surgery, radiotherapy
and chemotherapy have been the available therapies. How-
ever, despite improvements in these treatment methods
overall survival of patients with glioblastoma remains
extremelypoor[20].Detailedunderstandingofthemetabolic
pathwaysofglialtumourcellsandtheirdifferencestonormal
cells could provide potential targets for treatment. These can
be directed to block or manipulate speciﬁc pathways in
cancer cells to inhibit their metabolism and thus, growth.
Glucose is the primary energy substrate for the adult
mammalian brain; however lactate and ketone bodies can be
used as alternative energy substrates under stressful
and pathological conditions [28]. Ketone bodies include
b-hydroxybutyrate (BHB), acetoacetate and acetone, of
which the latter is generally considered of little metabolic
signiﬁcance. Under normal physiological conditions there is
a minimal accumulation of cerebral ketones with rapid uti-
lization, implying blood–brain barrier control of ketone
oxidation in the nonfasted adult human brain [24]. However,
in a hypoglycaemic state transport across the blood brain
barrierincreasesandthebrainmetabolizesalargeramountof
ketone bodies which bypass cytoplasmic glycolysis and
directly enter the TCA cycle as acetyl-CoA [35]. It has been
postulated that glioma cells lack the ability to metabolize
ketone bodies due to defects in the mitochondrial TCA cycle
andelectrontransportchain[31,32].Theketogenicdiet(KD)
isa high-fat, low-protein, low-carbohydrate diet used totreat
children with drug-resistant epilepsy [9, 32] and it has been
reported as beneﬁcial treatment for advanced glial tumors
[17]. However, the latter study consists of two case reports
only. Animal studies have been published showing positive
effects of the KD and hypoglycemia on glial tumours [32].
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enous lactate was the major substrate for oxidative
metabolism and that glucose was entering a different
compartment. However, there is a lack of studies that can
delineate the detailed metabolic pathways in glioma tumor
cells especially the ability of tumor cells to shift between
metabolic pathways under different conditions. Incubating
C6 cells (glioblastoma cell line) with [2,4-
13C]BHB fol-
lowed by biochemical analysis can give information about
C6 cells and normal animal cells metabolism. Using this
method the present study was performed to explore the
mitochondrial metabolic pathways in the C6 glioblastoma
cell line and cerebellar astrocytes in the presence and
absence of glucose. C6 cells were also incubated with
[1-
13C]glucose in the presence and absence of unlabeled
BHB to explore if BHB can substitute for glucose labelling.
Materials and Methods
Materials
The C6-glioma cell line was obtained from the ATCC-LGC
Promochem (Sweden) and stocksamples were kept inliquid
nitrogen. Plastic tissue culture dishes were purchased from
Nunc A/S (Roskilde, Denmark) and fetal calf serum (FCS)
from Seralab Ltd. (Sussex, UK). Dulbecco’s minimum
essential medium, unlabeled BHB and D(?)-glucose were
from Sigma Chemical Co. (St. Louis, MO, USA). Sodium
[2,4-
13C]BHB (99%) and [1-
13C]glucose (99%) were from
Cambridge Isotope Laboratories (Woburn, MA, USA),
and the GC/MS derivatization reagent MTBSTFA
(N-methyl-N-(tert-butyldimethylsilyl)triﬂuoroacetamide) ?
1% t-BDMS-Cl (tert-butyldimethylchlorosilane) was pur-
chased from Regis Technologies, Inc. (Morton Grove, IL,
USA). F-12 Kraighn’s Nutrient mixture and penicillin-
streptomycin liquid were purchased from Invitrogen Ltd
(Paisley, UK). All other chemicals were of the purest grade
available from regular commercial sources.
Cell Cultures
NMRI mice were obtained from Taconic M&B (Copen-
hagen, Denmark). Cerebellar astrocytes were cultured as
described earlier [10]i n7 5c m
2 ﬂasks. Brieﬂy, cerebellum
was taken from 7-day-old mice and passed through Nitex
nylon netting (80 lm pore size) into Dulbecco’s minimum
essential medium (DMEM) containing 20% (v/v) fetal calf
serum (FCS). Medium was changed 2 days after plating
and subsequently twice a week for 3 weeks gradually
decreasing the FCS concentration to 10%. Experiments
were performed with three-week-old cultures.
C6 cells were used after 36 passages. On day one
5 9 10
6 cells were seeded in 75 cm
2 ﬂasks and cultured
with F-12 media containing penicillin (10,000 units/ml),
streptomycin (10,000 lg/ml) and 15% (v/v) fetal calf
serum. Experiments were performed 2 days after seeding.
Experiments using [2,4-
13C]BHB or [1-
13C]glucose
Culture medium was replaced with 15 ml serum and glu-
tamine free DMEM containing 1 mM [2,4-
13C]BHB with
or without 3 mM glucose or 3 mM [1-
13C]glucose with
and without BHB. After 4 h the experimental medium was
removed and lyophilized. The cells were extracted with
70% ethanol and supernatants were lyophilized.
Protein Analysis
Cellular protein in the ethanol pellets was determined after
dissolving in 1 M KOH at 37C for 60 min, using the
Pierce BCA (Pierce, Rockford, IL, USA) protein assay
with bovine serum albumin as standard.
HPLC
Amino acids in medium and C6 cell extracts were quan-
tiﬁed by HPLC on a Hewlett Packard 1100 system (Agilent
Technologies, Palo Alto, CA, USA). The amino acids
were pre-column derivatized with o-phthaldialdehyde [8]
and subsequently separated on a ZORBAX SB-C18
(4.6 9 150 mm, 3.5 lm) column from Agilent using a
phosphate buffer (50 mM, pH = 5.9) and a solution of
methanol (98.75%) and tetrahydrofurane (1.25%) as elu-
ents. The separated amino acids were detected with ﬂuo-
rescence and compared to a standard curve derived from
standard solutions of amino acids. Total glutathione (i.e.,
glutathione plus glutathione disulﬁde) was determined
by HPLC as in [8] after derivatization with OPA after
reducing the sample with 5% (v/v) mercaptoethanol.
GC/MS
Lyophilized cell extracts were re-dissolved in HCl, adjus-
ted to pH\2 and dried under atmospheric air. The amino
acids were in multiple steps extracted into an organic phase
of ethanol and benzene and dried again under atmospheric
air before derivatization with MTBSTFA in the presence of
1% t-BDMS-Cl [14]. The samples were analyzed on a
Agilent 6890 gas chromatograph linked to a Agilent 5975B
mass spectrometer. Atom percent excess (
13C) was deter-
mined after allowing for naturally abundant
13C and silicon
(from silyl groups).
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1231H Magnetic Resonance Spectroscopy (MRS)
Lyophilized media samples were dissolved in 0.4 ml 99%
D2O containing 0.1% ethylene glycol. Proton MR spectra
were accumulated on Bruker DRX500 spectrometer
(BRUKER Analytik GmbH, Rheinstetten, Germany). The
following acquisition parameters were applied: 90 pulse
angle, an acquisition time of 1.36 s and a relaxation delay
of 10 s, 32 scans were accumulated for each sample. Water
suppression was achieved by applying a low-power pre-
saturation pulse at the water frequency.
Data Analysis
The glucose- and BHB consumption was calculated by
subtracting the amount of glucose or BHB (quantiﬁed from
1H spectra) present in the media from the known concen-
tration of the added glucose and BHB. Lactate production
was calculated from the
1H spectra.
Peaks from GC/MS spectra were integrated, and atom
percent excess values were calculated by comparison with
unlabeled standard solutions. Results are presented as
means ± standard deviation (SD). It was not considered
useful to compare metabolites between astrocytes and C6
cells. Thus, even though the experiment was carried out
with four groups, only same culture groups (two) were
analyzed statistically and thus Student’s t-test was the
appropriate test, and P\0.05 was considered statistically
signiﬁcant.
Results
The labeling pattern in glutamate, glutamine, aspartate and
malate from [2,4-
13C]BHB and [1-
13C]glucose after the
ﬁrst turn of the TCA cycle is shown in Fig. 1a.
[2,4-
13C]BHB enters the TCA cycle as [2-
13C]acetyl-CoA
after conversion to [2,4-
13C]acetoacetate and subsequently
[2,4-
13C]acetoacetyl-CoA. [2-
13C]Acetyl-CoA may con-
dense with unlabeled oxaloacetate. The subsequent steps
yield [4-
13C]a-ketoglutarate, which may be transaminated
to [4-
13C]glutamate and [4-
13C]glutamine giving rise mono
labeling (M ? 1) in the mass spectrum. If [4-
13C]a-keto-
glutarate is converted to succinyl-CoA, due to the sym-
metry of succinate, labeling of malate and oxaloacetate will
occur in either the C-2 or C-3 position. [2/3-
13C]Oxalo-
acetate can be transaminated to [2/3-
13C]aspartate which is
detected by GC–MS as a singlet (M ? 1). Alternatively
(Fig. 1b), [2/3-
13C]oxaloacetate may be condensed with
either labeled acetyl-CoA to form citrate, giving rise to
double labeling of the metabolites (M ? 2) or with unla-
bled acetyl-CoA to give mono labeled metabolites. Fig-
ure 2 shows the metabolism of pyruvate which can be
generated from glucose but not BHB. Pyruvate can be
carboxylated and can enter the TCA cycle as oxaloactate.
Both astrocytes and C6 cells metabolized glucose and
BHB efﬁciently (Table 1). Whereas astrocytes decreased
BHB consumption in the presence of glucose, the opposite
was the case for C6 cells. As expected in the presence of
glucose lactate production increased in both cell types
[ 2-13C]Acetyl-CoA
[4-13C]α-Ketoglutarate
[4-13C]Glutamine 
(M+1)
[2,4-13C]β-Hydroxybutyrate
[2,4-13C]Acetoacetate
[2,4-13C]Acetoacetyl-CoA
[2/3-13C]Oxaloacetate
[4-13C]Glutamate 
(M+1)
[2/3-13C]Aspartate
(M+1)
[2/3-13C]Malate
(M+1)
[1-13C]Glucose
[ 2-13C]Acetyl-CoA
Glutamine
(M+2)
Glutamate 
(M+2)
Aspartate 
(M+2)
Malate
(M+2)
1. Turn 2. Turn
(a)
(b)
Fig. 1 Schematic presentation of labeling of glutamate, glutamine,
aspartate and malate from [2,4-
13C]b-hydroxybutyrate and
[1-
13C]glucose from the ﬁrst turn of the TCA cycle (a). Condensation
of [2-
13C]acetyl-CoA with unlabeled oxaloacetate generates mono
label in the metabolites which is detected as M ? 1. The fate of the
13C from the second turn of the TCA cycle is indicated in (b). If
oxaloacetate is labeled in the C3 or C2 position and condenses with
[2-
13C]acetyl-CoA, the resulting metabolites are double labeled and
thus are detected by mass spectroscopy as M ? 2
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123(Table 1). The intracellular concentration of glutamate
increased in C6 cells in the presence of glucose whereas
glutamine and aspartate amounts remained unchanged
(Table 1).
Labelling from [2,4-
13C]BHB was decreased in glutamate
and malate in the presence of glucose in astrocytes and C6
cells and in aspartate in astrocytes (Fig. 3). This was evi-
denced by an increase in M (molecules without
13C) and a
decrease in both M ? 1a n dM? 2. Glutamine labeling in
both cell types and aspartate labeling in C6 cells was only
slightly affected by the presence of glucose (Fig. 3).
[1-
13C]glucose labeling of C6 cells in the presence and
absenceofBHBisshowninFig. 4.ItisapparentthatBHBhas
little inﬂuence on labeling from [1-
13C]glucose, only M ? 2
labeling in glutamate and malate are slightly decreased.
Figure 5 shows the amount of glutamine, glutamate,
aspartate and glutathione in the cell culture medium after
the 4 h incubation. The amounts of glutamine released to
the medium increased in astrocytes in the presence of
glucose whereas that of aspartate and glutathione decreased
(Fig. 5). The C6 cells released very little to the medium
except for glutamate, which was not quantiﬁable from
astrocytes in the absence of glucose.
Discussion
This study was undertaken to determine if the ketogenic
diet could be useful for glioblastoma patients. The
hypothesis tested was that whereas astrocytes (and neu-
rons) can function in the presence of ketone bodies [11,
15], this would not be the case for glioblastoma cells.
It is believed that cancer cells are dependent on gly-
colysis to meet their high energy demand and the results of
a number of studies have shown that this is also the case for
glioblastoma cells [21, 26]. The function of the TCA cycle
and oxidative metabolism in glioma cells is the subject of
controversy. It has been suggested that these cells have a
defective tricarboxylic acid (TCA) cycle and electron
transport chain and a reduced number of mitochondria as
well as a lower mitochondrial density [21]. Many investi-
gators have stressed the importance of glutamine as a
source of reduced nitrogen for maintenance of nucleotide
biosynthesis and that of nonessential amino acids and
proteins. In fact it has been shown that the human glio-
blastoma cell line SF188 avidly metabolizes glutamine to
lactate and this catabolism was also accompanied by
secretion of nitrogen as ammonia and alanine [4].
[2,4-13C]α-Ketoglutarate
[2,4-13C]Glutamine
[ 1-13C]Glucose
[ 3-13C]Pyruvate
[2-13C]Oxaloacetate
[2,4-13C]Glutamate
Pyruvate Carboxylase
[2-13C]Malate
Pyruvate Dehydrogenase
[ 2-13C]Acetyl-CoA
[ 2-13C]Aspartate
Fig. 2 Metabolism of [1-
13C]glucose which can be carboxylated to
yield net production of glutamate, glutamine and aspartate.
13C
labeling from the ﬁrst turn of the TCA cycle when both acetyl-CoA
and oxaloacetate are labeled is indicated only. Labeling from
pyruvate carboxylase will result in labeling in the C2 positions and
that from pyruvate dehydrogenase in the C4 positions of a-ketoglu-
tarate, glutamate and glutamine
Table 1 Lactate production, glucose and b-hydroxybutyrate (BHB) consumption in cerebellar astrocytes and C6 glioma cells and amounts of
glutamate, glutamine and aspartate in C6 glioma cells in the presence and absence of glucose
lmol/mg protein/4h Astrocytes BHB C6 BHB Astrocytes BHB?glucose C6 ? BHB?glucose
Glucose consumption 11.9 ± 2.2 15.3 ± 3.0
BHB consumption 1.9 ± 0.6 1.7 ± 0.7 1.4 ± 0.2* 2.4 ± 1.1*
Lactate production 2.9 ± 0.6 3.3 ± 0.5 10.5 ± 1.0* 13.4 ± 2.5*
nmol/mg protein/4 h
Glutamate n.d. 4.7 ± 0.6 n.d. 11.5 ± 4.2*
Glutamine n.d. 1.2 ± 0.6 n.d. 0.7 ± 0.3
Aspartate n.d. 3.3 ± 1.0 n.d. 2.4 ± 1.2
Cells (n = 6) were incubated for 4 h with serum and gluamine free DMEM containing 1 mM [2,4-
13C]hydroxybutyrate with or without 3 mM
glucose. Results for glucose, BHB and lactate were derived from
1H MRS and amounts of glutamate, glutamine and aspartate from HPLC and
are presented as means ± SD, and P\0.05 was considered statistically signiﬁcant. BHB = b-hydroxybutyrate, n.d. = not determined.
* Signiﬁcantly different from same group without glucose
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123In mammals glucose and glutamine are two of the most
abundant nutrients in plasma. Neurons, protected but also
isolated by the blood brain barrier, are particularly
dependent on the availability of both substrates. The blood
usually supplies the glucose, whereas astrocytes supply the
glutamine to neurons. The latter was conﬁrmed in the
present study. The C6 glioblastoma cells did not release
glutamine in agreement with an earlier study [6, 16, 23].
Moreover, in vivo in a glioma-bearing rat model it was
demonstrated that C6 cells do not synthesize glutamine
Fig. 3 Distribution of
13C label
(M, no label above natural
abundance; M ? 1, one
13C
atom; M ? 2, two
13C atoms) in
glutamate, glutamine, aspartate
and malate detected by mass
spectrometry in cell extracts of
cultured cerebellar astrocytes
(n = 6) and C6 cells (n = 6)
after incubation for 4 h with
serum and glutamine free
DMEM containing 1 mM
[2,4-
13C]b-hydroxybutyrate
with or without 3 mM glucose.
Results are presented as
means ± SD, and P\0.05 was
considered statistically
signiﬁcant, for details see
Methods
Fig. 4 Distribution of
13C label
(M, no label above natural
abundance; M ? 1, one
13C
atom; M ? 2, two
13C atoms) in
glutamate, glutamine, aspartate
and malate detected by mass
spectrometry in cell extracts of
cultured C6 cells (n = 3) after
incubation for 4 h with serum
and glutamine free DMEM
containing 3 mM
[1-
13C]glucose with or without
1 mM BHB. Results are
presented as means ± SD, and
P\0.05 was considered
statistically signiﬁcant, for
details see Methods
1570 Neurochem Res (2011) 36:1566–1573
123either and avidly take up glutamine directly from the blood
circulation to provide nitrogen needed during the glioma
growth [2].
In the present study the glioblastoma cells and astrocytes
were cultured in glucose and glutamine free environment to
test if they could survive under those conditions. The
ketone body BHB was added since neural cells with intact
mitochondria can survive under these conditions. Surpris-
ingly, both cell types tolerated the absence of glucose well
and mitochondrial metabolism was evidenced by avid
catabolism of [2,4-
13C]BHB. The lactate release observed
in the glucose free medium is possibly due to residual
glucose inside the cells and also intracellular alanine and
pyruvate conversion to lactate. The similarity in the lactate
production in the presence and absence of glucose between
astrocytes and C6 cells is also worth mentioning. It might
be related to the fact that the isoenzyme pattern of lactate
dehydrogenase in astrocytes in culture is not identical to
that of astrocytes in the adult brain [18]. Rodrigues et al.
[27] reported lactate recycling in C6 cells incubated with
glucose and lactate or pyruvate but not in the presence of
glucose alone. In the present study it was not possible to
determine such recycling.
The astrocytes released glutamine even in the absence of
glucose whereas C6 cells secreted glutamate. It has been
shown that elevated levels of extracelluler glutamate can
stimulate tumor cell proliferation and motility via autocrine
or paracrine activation of glutamate receptors and enhance
invasion of the surrounding tissue by causing excitotoxic
damage to normal brain and necrosis in glioblastoma [5,
13, 19]. Elevated extracellular glutamate levels have been
shown to be caused by increased synthesis and release and
impaired glutamate uptake in glioblastoma [36]. Gluta-
mate, mainly from glutamine, is released via the cystine-
glutamate exchanger found on glioma cell membranes [36].
Cystine, which was present in the incubation medium, is
an essential precursor for the biosynthesis of glutathione
that protects cells (including glioma) from endogenously
produced oxidative damage [3, 12, 34]. In the present
study, experimental medium from astrocytes contained
glutathione, whereas almost none was found in that from
C6 cells indicating that astrocytes can help protect neurons
by release of glutathione [7] but this is not the case for the
C6 cells.
Metabolism of [1-
13C]glucose by astrocytes is well
documented and glutamine production and pyruvate car-
boxylation is prevalent [22, 33, 37]. Incubating C6 cells
with [1-
13C]glucose, however, showed that they have very
little label in glutamine, showing that glutamine synthesis
is extremely small in C6 cells as also shown by Portais
et al. [23] and the same holds for aspartate. Glutamate and
malate labeling is only slightly smaller from [1-
13C]glu-
cose than [2,4-
13C]BHB.
In the presence of glucose, astrocytes and C6 cells
reacted differently. Whereas astrocytes decreased their
BHB consumption slightly, the opposite was the case for
the C6 cells. Astrocytes used glucose in their TCA cycle as
evidenced by decreased labelling of glutamate and aspar-
tate from [2,4-
13C]BHB which was not the case in C6 cells.
Furthermore, astrocytes were able to increase the amounts
of glutamate, glutamine and aspartate inside the cells and
their release of glutamine to the medium. This is an indi-
cation of their capacity for anaplerosis and thus pyruvate
carboxylation most likely via pyruvate carboxylase [25].
Only approximately half of the glucose was released as
lactate both from astrocytes and C6 cells. This is surprising
since in the absence of BHB most of the glucose is used for
lactate production at a 3 mM glucose concentration in the
incubation medium [30]. It appears that BHB increases
mitochondrial metabolism of glucose in both cell types. C6
cells did not show any indication for carboxylation, which
can be accomplished via pyruvate carboxylase or malic
Fig. 5 Content of glutamate, aspartate, glutamine and glutathione
detected by HPLC in medium of cultured cerebellar astrocytes and C6
cells. Cells were incubated for 4 h with serum and glutamine free
DMEM containing 1 mM [2,4-
13C]b-hydroxybutyrate with or without
3 mM glucose. Results are presented as means ± SD, and P\0.05
was considered statistically signiﬁcant, for details see Methods.
* Signiﬁcantly different from same group without glucose
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123enzyme. This is in agreement with previous studies [4, 23]
which have reported entry of pyruvate into the TCA cycle
via pyruvate dehydrogenase but not pyruvate carboxylase.
Taken together these results show clearly that C6 cells have
a functioning TCA cycle that can utilize ketone bodies but
do not perform anaplerosis. C6 cells release glutamate
whereas astrocytes release glutamine and glutathione.
Acknowledgment The excellent technical assistance of Bente
Urfjell and Lars Evje is gratefully acknowledged.
Open Access This article is distributed under the terms of the
Creative Commons Attribution Noncommercial License which per-
mits any noncommercial use, distribution, and reproduction in any
medium, provided the original author(s) and source are credited.
References
1. Bouzier AK, Voisin P, Goodwin R, Canioni P, Merle M (1998)
Glucose and lactate metabolism in C6 glioma cells: evidence for
the preferential utilization of lactate for cell oxidative metabo-
lism. Dev Neurosci 20(4–5):331–338
2. Bouzier AK, Quesson B, Valeins H, Canioni P, Merle M (1999)
[1–13C]glucose metabolism in the tumoral and nontumoral
cerebral tissue of a glioma-bearing rat. J Neurochem
72(6):2445–2455
3. Chung WJ, Lyons SA, Nelson GM, Hamza H, Gladson CL,
Gillespie GY, Sontheimer H (2005) Inhibition of cystine uptake
disrupts the growth of primary brain tumors. J Neurosci
25(31):7101–7110
4. DeBerardinis RJ, Mancuso A, Daikhin E, Nissim I, Yudkoff M,
Wehrli S, Thompson CB (2007) Beyond aerobic glycolysis:
transformed cells can engage in glutamine metabolism that
exceeds the requirement for protein and nucleotide synthesis.
Proc Natl Acad Sci 104(49):19345–19350
5. De Groot JF, Liu TJ, Fuller G, Yung WK (2005) The excitatory
amino acid transporter-2 induces apoptosis and decreases glioma
growth in vitro and in vivo. Cancer Res 65(5):1934–1940
6. Dolin ´ska M, Dybel A, Hilgier W, Zielin ´ska M, Zabłocka B,
Buzan ´ska L, Albrecht J (2001) Glutamine transport in C6 glioma
cells: substrate speciﬁcity and modulation in a glutamine
deprived culture medium. J Neurosci Res 66(5):959–966
7. Dringen R, Hirrlinger J (2003) Glutathione pathways in the brain.
Biol Chem 384(4):505–516
8. Geddes JW, Wood JD (1984) Changes in the amino acid content
of nerve endings (synaptosomes) induced by drugs that alter the
metabolism of glutamate and gamma-aminobutyric acid. J Neu-
rochem 42:16–24
9. Greene AE, Todorova MT, Seyfried TN (2003) Perspectives on
the metabolic management of epilepsy through dietary reduction
of glucose and elevation of ketone bodies. J Neurochem
86(3):529–537
10. Hertz L, Juurlink BHJ, Hertz E, Fosmark H, Schousboe A (1989)
Preparation of primary cultures of mouce (rat): astrocytes. In:
Shahar A, De Vellis J, Vernadakis A, Haber B (eds) A dissection
and tissue culture manual for the nervous system. Alan R. Liss,
New York, pp 105–108
11. Kunnecke B, Cerdan S, Seelig J (1993) Cerebral metabolism of
[1, 2–13C2]glucose and [U-13C4]3-hydroxybutyrate in rat brain
as detected by 13C NMR spectroscopy. NMR Biomed
6(4):264–277
12. Lewerenz J, Klein M, Methner A (2006) Cooperative action of
glutamate transporters and cystine/glutamate antiporter system
Xc- protects from oxidative glutamate toxicity. J Neurochem
98(3):916–925
13. Lyons SA, Chung WJ, Weaver AK, Ogunrinu T, Sontheimer H
(2007) Autocrine glutamate signaling promotes glioma cell
invasion. Cancer Res 67(19):9463–9471
14. Mawhinney TP, Robinett RS, Atalay A, Madson MA (1986)
Analysis of amino acids as their tert.-butyldimethylsilyl deriva-
tives by gas-liquid chromatography and mass spectrometry.
J Chromatogr 358:231–242
15. Melo TM, Nehlig A, Sonnewald U (2006) Neuronal-glial inter-
actions in rats fed a ketogenic diet. Neurochem Int 48(6–7):498–
507
16. Merle M, Pianet I, Canioni P, Labouesse J (1992) Comparative
31P and
1H NMR studies on rat astrocytes and C6 glioma cells in
culture. Biochimie 74(9–10):919–930
17. Nebeling LC, Miraldi F, Shurin SB, Lerner E (1995) Effects of a
ketogenic diet on tumor metabolism and nutritional status in
pediatric oncology patients: two case reports. J Am Coll Nutr
14(2):202–208
18. Nissen C, Schousboe A (1979) Activity and isoenzyme pattern of
lactate dehydrogenase in astroblasts cultured from brains of
newborn mice. J Neurochem 32(6):1787–1792
19. Noch E, Khalili K (2009) Molecular mechanisms of necrosis in
glioblastoma: the role of gutamate excitotoxicity. Cancer Biol
Ther 8(19):1791–1797
20. Ohgaki H, Dessen P, Jourde B, Horstmann S, Nishikawa T, Di
Patre PL, Burkhard C, Schu ¨ler D, Probst-Hensch NM, Maiorka
PC, Baeza N, Pisani P, Yonekawa Y, Yasargil MG, Lu ¨tolf UM,
Kleihues P (2004) Genetic pathways to glioblastoma: a popula-
tion-based study. Cancer Res 64(19):6892–6899
21. Oudard S, Boitier E, Miccoli L, Rousset S, Dutrillaux B, Poupon
MF (1997) Gliomas are driven by glycolysis: putative roles of
hexokinase, oxidative phosphorylation and mitochondrial ultra-
structure. Anticancer Res 17(3C):1903–1911
22. Portais JC, Pianet I, Allard M, Merle M, Raffard G, Kien P, Biran
M, Labouesse J, Caille JM, Canioni P (1991) Magnetic resonance
spectroscopy and metabolism. Applications of proton and
13C
NMR to the study of glutamate metabolism in cultured glial cells
and human brain in vivo. Biochimie 73(1):93–97
23. Portais JC, Schuster R, Merle M, Canioni P (1993) Metabolic ﬂux
determination in C6 glioma cells using carbon-13 distribution
upon [1–13C]glucose incubation. Eur J Biochem 217(1):457–468
24. Pan JW, de Graaf RA, Petersen KF, Shulman GI, Hetherington
HP, Rothman DL (2002) [2, 4–13C2]-beta-Hydroxybutyrate
metabolism in human brain. J Cereb Blood Flow Metab
22(7):890–898
25. Qu H, Eloqayli H, Unsga ˚rd G, Sonnewald U (2001) Glutamate
decreases pyruvate carboxylase activity and spares glucose as
energy substrate in cultured cerebellar astrocytes. J Neurosci Res
66(6):1127–1132
26. Roslin M, Henriksson R, Bergstrom P, Ungerstedt U, Bergenheim
AT (2003) Baseline levels of glucose metabolites, glutamate and
glycerol in malignant glioma assessed by stereotactic microdi-
alysis. J Neurooncol 61(2):151–160
27. Rodrigues TB, Gray HL, Benito M, Garrido S, Sierra A, Geraldes
CF, Ballesteros P, Cerda ´n S (2005) Futile cycling of lactate
through the plasma membrane of C6 glioma cells as detected by
(13C, 2H) NMR. J Neurosci Res 79(1–2):119–127
28. Schurr A, Payne RS, Miller JJ, Rigor BM (1997) Brain lactate,
not glucose, fuels the recovery of synaptic function from
hypoxia upon reoxygenation: an in vitro study. Brain Res
744(1):105–111
30. Schousboe A, Westergaard N, Waagepetersen HS, Larsson OM,
Bakken IJ, Sonnewald U (1997) Trafﬁcking between glia and
1572 Neurochem Res (2011) 36:1566–1573
123neurons of TCA cycle intermediates and related metabolites. Glia
21(1):99–105
31. Seyfried TN, Kiebish M, Mukherjee P, Marsh J (2008) Targeting
energy metabolism in brain cancer with calorically restricted
ketogenic diets. Epilepsia 49(Suppl 8):114–116
32. Seyfried TN, Sanderson TM, El-Abbadi MM, McGowan R,
Mukherjee P (2003) Role of glucose and ketone bodies in the
metabolic control of experimental brain cancer. Br J Cancer
89(7):1375–1382
33. Sonnewald U, Westergaard N, Hassel B, Mu ¨ller TB, Unsga ˚rd G,
Fonnum F, Hertz L, Schousboe A, Petersen SB (1993) NMR
spectroscopic studies of
13C acetate and
13C glucose metabolism
in neocortical astrocytes: evidence for mitochondrial heteroge-
neity. Dev Neurosci 15(3–5):351–358
34. Sontheimer H (2008) A role for glutamate in growth and invasion
of primary brain tumors. J Neurochem 105(2):287–295
35. Veech RL, Chance B, Kashiwaya Y, Lardy HA, Cahill GF Jr
(2001) Ketone bodies, potential therapeutic uses. IUBMB Life
51(4):241–247
36. Ye ZC, Sontheimer H (1999) Glioma cells release excitotoxic
concentrations of glutamate. Cancer Res 59:4383–4391
37. Zwingmann C, Leibfritz D (2003) Regulation of glial metabolism
studied by
13C-NMR. NMR Biomed 16(6–7):370–399
Neurochem Res (2011) 36:1566–1573 1573
123